IL108750A - Pharmaceutical cognition enhancing compositions containing 1,3-dialiphatic-8-(phenylalkyl or ludanyl) xanthines as selective adenosine receptor agents - Google Patents
Pharmaceutical cognition enhancing compositions containing 1,3-dialiphatic-8-(phenylalkyl or ludanyl) xanthines as selective adenosine receptor agentsInfo
- Publication number
- IL108750A IL108750A IL10875094A IL10875094A IL108750A IL 108750 A IL108750 A IL 108750A IL 10875094 A IL10875094 A IL 10875094A IL 10875094 A IL10875094 A IL 10875094A IL 108750 A IL108750 A IL 108750A
- Authority
- IL
- Israel
- Prior art keywords
- ludanyl
- dialiphatic
- xanthines
- phenylalkyl
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2350193A | 1993-02-26 | 1993-02-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL108750A0 IL108750A0 (en) | 1994-05-30 |
| IL108750A true IL108750A (en) | 2000-09-28 |
Family
ID=21815459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL10875094A IL108750A (en) | 1993-02-26 | 1994-02-23 | Pharmaceutical cognition enhancing compositions containing 1,3-dialiphatic-8-(phenylalkyl or ludanyl) xanthines as selective adenosine receptor agents |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5840729A (hu) |
| EP (1) | EP0686155B1 (hu) |
| JP (1) | JPH08512281A (hu) |
| KR (1) | KR100315898B1 (hu) |
| CN (1) | CN1041418C (hu) |
| AT (1) | ATE169019T1 (hu) |
| AU (1) | AU680241B2 (hu) |
| CA (1) | CA2155130C (hu) |
| DE (1) | DE69412073T2 (hu) |
| DK (1) | DK0686155T3 (hu) |
| ES (1) | ES2120025T3 (hu) |
| HU (1) | HUT72677A (hu) |
| IL (1) | IL108750A (hu) |
| MX (1) | MX9401406A (hu) |
| NO (1) | NO311920B1 (hu) |
| NZ (1) | NZ262984A (hu) |
| TW (1) | TW261532B (hu) |
| WO (1) | WO1994019349A1 (hu) |
| ZA (1) | ZA941176B (hu) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303624B1 (en) * | 1997-03-18 | 2001-10-16 | Fujisawa Pharmaceutical Co., Ltd. | Preventives and remedies for hyperphosphatemia |
| DZ2805A1 (fr) | 1998-06-02 | 2005-01-30 | Cadus Pharmaceutical Corp | Composition à pyrroloÄ2,,3dÜ pyrimidine et leurs usages. |
| US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US20020115635A1 (en) * | 2001-02-21 | 2002-08-22 | Pnina Fishman | Modulation of GSK-3beta activity and its different uses |
| JP2005529062A (ja) | 2001-11-30 | 2005-09-29 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | アデノシンａ１及びａ３受容体に特異的な化合物とその使用 |
| EP1465631B1 (en) | 2001-12-20 | 2010-02-24 | OSI Pharmaceuticals, Inc. | Pyrimidine a2b selective antagonist compounds, their synthesis and use |
| JP2005538950A (ja) * | 2002-05-15 | 2005-12-22 | ジェンザイム、コーポレーション | ２−アルキルシステイン、２−（ヒドロキシル化フェニル）−４−アルキルチアゾリン−４−カルボン酸およびそれらの誘導体の合成 |
| WO2004086047A2 (en) * | 2003-03-28 | 2004-10-07 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a1 (adora1) |
| EP1709966A4 (en) * | 2003-12-09 | 2009-04-29 | PREVENTIVE AND / OR THERAPEUTIC AGENT FOR SEVERE CEREBRAL DYSFUNCTION | |
| US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| WO2007095161A2 (en) * | 2006-02-14 | 2007-08-23 | New York University | Methods and compositions for treating disorders associated with increased bone turnover and osteopenia |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE8817122U1 (de) * | 1988-12-22 | 1993-02-04 | Boehringer Ingelheim Kg, 55218 Ingelheim | Neue Xanthinderivate mit Adenosinantogenistischer Wirkung |
| US5047534A (en) * | 1990-03-26 | 1991-09-10 | Merrell Dow Pharmaceuticals Inc. | Selective adenosine receptor agents |
| DE4019892A1 (de) * | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
| JPH0455150A (ja) * | 1990-06-22 | 1992-02-21 | Takata Kk | 助手席用エアバッグ装置 |
| US5087827A (en) * | 1991-02-11 | 1992-02-11 | Tektronix, Inc. | Variable voltage transition circuit |
| US5208240A (en) * | 1991-03-12 | 1993-05-04 | Merrell Dow Pharmaceuticals Inc. | 8-substituted purines as selective adenosine receptor agents |
| US5281607B1 (en) * | 1992-10-08 | 1998-05-19 | Univ New York | Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases |
-
1994
- 1994-01-27 JP JP6518986A patent/JPH08512281A/ja active Pending
- 1994-01-27 AT AT94910661T patent/ATE169019T1/de not_active IP Right Cessation
- 1994-01-27 NZ NZ262984A patent/NZ262984A/en unknown
- 1994-01-27 AU AU62968/94A patent/AU680241B2/en not_active Ceased
- 1994-01-27 HU HU9502495A patent/HUT72677A/hu unknown
- 1994-01-27 DE DE69412073T patent/DE69412073T2/de not_active Expired - Fee Related
- 1994-01-27 KR KR1019950703577A patent/KR100315898B1/ko not_active IP Right Cessation
- 1994-01-27 US US08/500,991 patent/US5840729A/en not_active Expired - Fee Related
- 1994-01-27 EP EP94910661A patent/EP0686155B1/en not_active Expired - Lifetime
- 1994-01-27 CN CN94191309A patent/CN1041418C/zh not_active Expired - Fee Related
- 1994-01-27 DK DK94910661T patent/DK0686155T3/da active
- 1994-01-27 WO PCT/US1994/001009 patent/WO1994019349A1/en active IP Right Grant
- 1994-01-27 CA CA002155130A patent/CA2155130C/en not_active Expired - Fee Related
- 1994-01-27 ES ES94910661T patent/ES2120025T3/es not_active Expired - Lifetime
- 1994-02-21 ZA ZA941176A patent/ZA941176B/xx unknown
- 1994-02-22 TW TW083101485A patent/TW261532B/zh active
- 1994-02-23 IL IL10875094A patent/IL108750A/xx not_active IP Right Cessation
- 1994-02-24 MX MX9401406A patent/MX9401406A/es not_active IP Right Cessation
-
1995
- 1995-08-25 NO NO19953353A patent/NO311920B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0686155A1 (en) | 1995-12-13 |
| US5840729A (en) | 1998-11-24 |
| HUT72677A (en) | 1996-05-28 |
| KR100315898B1 (ko) | 2002-02-28 |
| IL108750A0 (en) | 1994-05-30 |
| ZA941176B (en) | 1994-09-20 |
| JPH08512281A (ja) | 1996-12-24 |
| HU9502495D0 (en) | 1995-10-30 |
| AU680241B2 (en) | 1997-07-24 |
| MX9401406A (es) | 1994-08-31 |
| DE69412073D1 (de) | 1998-09-03 |
| CA2155130C (en) | 1994-09-01 |
| NZ262984A (en) | 1997-05-26 |
| ES2120025T3 (es) | 1998-10-16 |
| AU6296894A (en) | 1994-09-14 |
| CN1041418C (zh) | 1998-12-30 |
| CN1118599A (zh) | 1996-03-13 |
| NO953353D0 (no) | 1995-08-25 |
| WO1994019349A1 (en) | 1994-09-01 |
| EP0686155B1 (en) | 1998-07-29 |
| NO311920B1 (no) | 2002-02-18 |
| ATE169019T1 (de) | 1998-08-15 |
| CA2155130A1 (en) | 1994-09-01 |
| DE69412073T2 (de) | 1999-02-18 |
| DK0686155T3 (da) | 1999-02-01 |
| TW261532B (hu) | 1995-11-01 |
| NO953353L (no) | 1995-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL117848A0 (en) | Novel compounds a process for their production and pharmacetical compositions containing same | |
| IL108520A0 (en) | Imidazopyridine derivatives, processes for the preparation thereof, and pharmaceutical compositions containing them | |
| EP0664792A4 (en) | ANTAGONISTS OF FIBRINOGENIC RECEPTORS. | |
| IL132153A0 (en) | Novel compounds | |
| NO952229L (no) | Anvendelse av karbamazepin og okskarbazepin ved behandling av neurologiske lesjoner relatert til traumatiske skader | |
| HU9502065D0 (en) | Application of carbamazepine and oxcarbazepine in the treatment of parkinson's disease and parkinsonian syndromes | |
| GB9416442D0 (en) | Therapeutic heterocycles | |
| IL108750A (en) | Pharmaceutical cognition enhancing compositions containing 1,3-dialiphatic-8-(phenylalkyl or ludanyl) xanthines as selective adenosine receptor agents | |
| EE9900315A (et) | Pürrolo[3,4-d]pürimidinooni derivaadid ja nende kasutamine ravimitena | |
| IL124091A (en) | Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the preparation of pharmaceutical compositions for the treatment of amyotrophic lateral sclerosis and pharmaceutical compositions containing it | |
| IL112999A0 (en) | Crystalline salts of 2,3,4,5- tetrahydro -1h-3-benzazepine compounds, their preparation and pharmaceutical compositions containing them | |
| FI932490A0 (fi) | Underenhetsvaccin mot Neisseria meningitidis-infektioner och motsvarande underenheter i rent tillstaond | |
| GB9507883D0 (en) | Compounds | |
| GR3024048T3 (en) | Sugar derivatives of macrolides. | |
| IL107917A0 (en) | Triazoloquinazolines, their preparation and their use as medicaments | |
| ZA9427B (en) | Use of riluzole for promoting restoration following radiation | |
| MX9802000A (es) | Sales de adicion de acido de compuestos de 2,3,4,5-tetrahidro-1h-3-benzacepina. | |
| NZ304823A (en) | Beta carboline derivatives and medicaments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| RH1 | Patent not in force |